Flexible design and efficient implementation of adaptive dose-finding studies

被引:15
|
作者
Weir, Christopher J.
Spiegelhalter, David J.
Grieve, Andrew P.
机构
[1] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Glasgow, Gardiner Inst, Western Infirm, Div Cardiovasc Med Sci, Glasgow G12 8QQ, Lanark, Scotland
[3] Inst Publ Hlth, MRC Biostat Unit, Cambridge, England
[4] Kings Coll London, Sch Med, Dept Publ Hlth Sci, Div Hlth & Social Care Res, London WC2R 2LS, England
基金
英国医学研究理事会;
关键词
acute stroke; Bayesian adaptive design; Markov chain Monte Carlo; normal dynamic linear model;
D O I
10.1080/10543400701643947
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A dose-finding study with an adaptive design generates three computational problems: fitting the dose-response curve given the current data, identifying the dose to be given to the next patient that is optimal for learning about the dose-response curve, and pretrial simulation in order to establish operating characteristics of alternative designs. Identifying the 'optimal' dose is the rate-limiting step since conventional methods, estimating the full posterior predictive distribution of some utility function under each of the possible doses, are very slow. We explore a simpler strategy based on importance sampling, whereby the posterior mean of the utility at each candidate dose is estimated by taking its average across an empirical distribution for the model parameters from the current Markov chain Monte Carlo (MCMC) run, weighted according to the likelihood of one or more predicted observations. We identify appropriate settings for this algorithm and illustrate its application in the context of a normal dynamic linear model used in a dose-finding clinical trial of a neutrophil inhibitory factor in acute ischaemic stroke.
引用
收藏
页码:1033 / 1050
页数:18
相关论文
共 50 条
  • [21] DOSE-FINDING AND PREMEDICATION STUDIES WITH ZOPICLONE
    DUNDEE, JW
    ELWOOD, RJ
    HILDEBRAND, PJ
    SINGLETON, M
    PHARMACOLOGY, 1983, 27 : 210 - 215
  • [22] Optimal Stopping of Adaptive Dose-Finding Trials
    Nasrollahzadeh, Amir Ali
    Khademi, Amin
    SERVICE SCIENCE, 2020, 12 (2-3) : 80 - 99
  • [23] Bayesian Adaptive Randomization in Dose-Finding Trials
    Ventz, Steffen
    Alexander, Brian M.
    Trippa, Lorenzo
    JAMA NETWORK OPEN, 2018, 1 (08)
  • [24] An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
    Rongji Mu
    Zongliang Hu
    Guoying Xu
    Haitao Pan
    BMC Medical Research Methodology, 21
  • [25] An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
    Mu, Rongji
    Hu, Zongliang
    Xu, Guoying
    Pan, Haitao
    BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [26] Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes
    Ryeznik, Yevgen
    Sverdlov, Oleksandr
    Hooker, Andrew C.
    AAPS JOURNAL, 2018, 20 (01):
  • [27] Recent developments in adaptive designs for phase I/II dose-finding studies
    Zohar, Sarah
    Chevret, Sylvie
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) : 1071 - 1083
  • [28] Adaptive optimal designs for dose-finding studies based on sigmoid Emax models
    Wang, Tianhua
    Yang, Min
    JOURNAL OF STATISTICAL PLANNING AND INFERENCE, 2014, 144 : 188 - 197
  • [29] Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
    Iasonos, Alexia
    Wages, Nolan A.
    Conaway, Mark R.
    Cheung, Ken
    Yuan, Ying
    O'Quigley, John
    STATISTICS IN MEDICINE, 2016, 35 (21) : 3760 - 3775
  • [30] BAYESIAN OPTIMAL ADAPTIVE DESIGNS FOR DELAYED-RESPONSE DOSE-FINDING STUDIES
    Li, Wen
    Fu, Haoda
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (05) : 888 - 901